Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel Free AMGN Stock Alerts

Amgen (AMGN) Competitors

Amgen logo
$415.21 -2.63 (-0.63%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$414.50 -0.71 (-0.17%)
As of 08/14/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AMGN vs. GILD, MRNA, VRTX, ABBV, and AZN

Should you buy Amgen stock or one of its competitors? Amgen's main competitors and comparable companies include Gilead Sciences (GILD), Moderna (MRNA), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), and Astrazeneca (AZN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Amgen compare to Gilead Sciences?

Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Amgen currently has a consensus target price of $372.39, indicating a potential downside of 10.31%. Gilead Sciences has a consensus target price of $158.04, indicating a potential upside of 14.22%. Given Gilead Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
3 Sell rating(s)
15 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.35
Gilead Sciences
0 Sell rating(s)
5 Hold rating(s)
24 Buy rating(s)
0 Strong Buy rating(s)
2.83

Amgen has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

76.5% of Amgen shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 0.9% of Amgen shares are held by insiders. Comparatively, 0.3% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Amgen has a net margin of 22.95% compared to Gilead Sciences' net margin of -10.64%. Amgen's return on equity of 124.14% beat Gilead Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen22.95% 124.14% 13.18%
Gilead Sciences -10.64%-2.11%-0.75%

In the previous week, Gilead Sciences had 6 more articles in the media than Amgen. MarketBeat recorded 38 mentions for Gilead Sciences and 32 mentions for Amgen. Amgen's average media sentiment score of 0.99 beat Gilead Sciences' score of 0.91 indicating that Amgen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
23 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Gilead Sciences
21 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

Gilead Sciences has lower revenue, but higher earnings than Amgen. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$36.75B6.11$7.71B$16.0925.81
Gilead Sciences$29.44B5.83$8.51B-$2.67N/A

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.4%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.4%. Amgen pays out 62.6% of its earnings in the form of a dividend. Gilead Sciences pays out -122.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has increased its dividend for 14 consecutive years and Gilead Sciences has increased its dividend for 10 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Amgen beats Gilead Sciences on 13 of the 20 factors compared between the two stocks.

How does Amgen compare to Moderna?

Moderna (NASDAQ:MRNA) and Amgen (NASDAQ:AMGN) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Moderna currently has a consensus price target of $42.13, indicating a potential downside of 33.46%. Amgen has a consensus price target of $372.39, indicating a potential downside of 10.31%. Given Amgen's stronger consensus rating and higher probable upside, analysts plainly believe Amgen is more favorable than Moderna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Moderna
5 Sell rating(s)
9 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
1.88
Amgen
3 Sell rating(s)
15 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.35

Moderna has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Amgen has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market.

75.3% of Moderna shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 0.9% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Amgen had 23 more articles in the media than Moderna. MarketBeat recorded 32 mentions for Amgen and 9 mentions for Moderna. Amgen's average media sentiment score of 0.99 beat Moderna's score of 0.48 indicating that Amgen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Moderna
2 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Amgen
23 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Amgen has a net margin of 22.95% compared to Moderna's net margin of -141.43%. Amgen's return on equity of 124.14% beat Moderna's return on equity.

Company Net Margins Return on Equity Return on Assets
Moderna-141.43% -28.30% -19.39%
Amgen 22.95%124.14%13.18%

Amgen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moderna$2.21B11.44-$2.82B-$7.99N/A
Amgen$36.75B6.11$7.71B$16.0925.81

Summary

Amgen beats Moderna on 14 of the 17 factors compared between the two stocks.

How does Amgen compare to Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Amgen (NASDAQ:AMGN) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Vertex Pharmaceuticals presently has a consensus price target of $563.50, indicating a potential upside of 11.42%. Amgen has a consensus price target of $372.39, indicating a potential downside of 10.31%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vertex Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
20 Buy rating(s)
1 Strong Buy rating(s)
2.92
Amgen
3 Sell rating(s)
15 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.35

Vertex Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Amgen has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 0.9% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$12.59B10.20$3.95B$17.1829.44
Amgen$36.75B6.11$7.71B$16.0925.81

Vertex Pharmaceuticals has a net margin of 35.00% compared to Amgen's net margin of 22.95%. Amgen's return on equity of 124.14% beat Vertex Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Vertex Pharmaceuticals35.00% 23.09% 16.72%
Amgen 22.95%124.14%13.18%

In the previous week, Amgen had 8 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 32 mentions for Amgen and 24 mentions for Vertex Pharmaceuticals. Amgen's average media sentiment score of 0.99 beat Vertex Pharmaceuticals' score of 0.32 indicating that Amgen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vertex Pharmaceuticals
8 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
4 Negative mention(s)
2 Very Negative mention(s)
Neutral
Amgen
23 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Vertex Pharmaceuticals beats Amgen on 9 of the 16 factors compared between the two stocks.

How does Amgen compare to AbbVie?

Amgen (NASDAQ:AMGN) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

76.5% of Amgen shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.9% of Amgen shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Amgen has higher earnings, but lower revenue than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$36.75B6.11$7.71B$16.0925.81
AbbVie$61.16B7.20$4.23B$3.5470.40

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.4%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.8%. Amgen pays out 62.6% of its earnings in the form of a dividend. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has raised its dividend for 14 consecutive years and AbbVie has raised its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen presently has a consensus price target of $372.39, suggesting a potential downside of 10.31%. AbbVie has a consensus price target of $275.50, suggesting a potential upside of 10.55%. Given AbbVie's stronger consensus rating and higher possible upside, analysts clearly believe AbbVie is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
3 Sell rating(s)
15 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.35
AbbVie
0 Sell rating(s)
5 Hold rating(s)
19 Buy rating(s)
2 Strong Buy rating(s)
2.88

Amgen has a net margin of 22.95% compared to AbbVie's net margin of 9.80%. Amgen's return on equity of 124.14% beat AbbVie's return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen22.95% 124.14% 13.18%
AbbVie 9.80%-422.07%14.34%

Amgen has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

In the previous week, AbbVie had 29 more articles in the media than Amgen. MarketBeat recorded 61 mentions for AbbVie and 32 mentions for Amgen. AbbVie's average media sentiment score of 1.12 beat Amgen's score of 0.99 indicating that AbbVie is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
23 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
AbbVie
41 Very Positive mention(s)
10 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

AbbVie beats Amgen on 12 of the 20 factors compared between the two stocks.

How does Amgen compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and Amgen (NASDAQ:AMGN) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Astrazeneca has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, Amgen has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.8%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.4%. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Amgen pays out 62.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has increased its dividend for 14 consecutive years.

Astrazeneca presently has a consensus target price of $211.00, indicating a potential upside of 34.93%. Amgen has a consensus target price of $372.39, indicating a potential downside of 10.31%. Given Astrazeneca's stronger consensus rating and higher possible upside, analysts plainly believe Astrazeneca is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Astrazeneca
1 Sell rating(s)
2 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.73
Amgen
3 Sell rating(s)
15 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.35

Amgen has a net margin of 22.95% compared to Astrazeneca's net margin of 17.02%. Amgen's return on equity of 124.14% beat Astrazeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
Astrazeneca17.02% 31.45% 13.20%
Amgen 22.95%124.14%13.18%

In the previous week, Amgen had 18 more articles in the media than Astrazeneca. MarketBeat recorded 32 mentions for Amgen and 14 mentions for Astrazeneca. Amgen's average media sentiment score of 0.99 beat Astrazeneca's score of 0.81 indicating that Amgen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Astrazeneca
7 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Amgen
23 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.9% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Astrazeneca has higher revenue and earnings than Amgen. Astrazeneca is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Astrazeneca$58.74B4.13$10.23B$6.6923.38
Amgen$36.75B6.11$7.71B$16.0925.81

Summary

Amgen beats Astrazeneca on 13 of the 19 factors compared between the two stocks.

Get Amgen News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMGN vs. The Competition

Export
MetricAmgenBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$225.90B$3.72B$7.02B$13.07B
Dividend Yield2.41%3.69%2.57%10.45%
P/E Ratio25.8110.72270.7225.33
Price / Sales6.111,233.84574.3573.89
Price / Cash12.36102.8870.4850.90
Price / Book19.2016.7812.926.25
Net Income$7.71B-$13.32M$3.45B$347.82M
7 Day Performance1.04%1.75%1.15%1.08%
1 Month Performance15.88%1.13%1.37%0.82%
1 Year Performance40.05%54.35%62.52%20.99%

Amgen Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMGN
Amgen
3.8435 of 5 stars		$415.21
-0.6%		$372.39
-10.3%		+43.0%$225.90B$36.75B25.8131,500
GILD
Gilead Sciences
4.4335 of 5 stars		$130.26
-3.7%		$158.04
+21.3%		+16.2%$161.94B$29.44B17.7717,000
MRNA
Moderna
1.3546 of 5 stars		$56.65
-0.6%		$42.13
-25.6%		+137.2%$22.60B$1.94BN/A4,700
VRTX
Vertex Pharmaceuticals
4.4188 of 5 stars		$482.76
+0.8%		$562.74
+16.6%		+29.6%$122.65B$12.00B28.666,400
ABBV
AbbVie
4.9078 of 5 stars		$245.31
+0.6%		$272.76
+11.2%		+21.7%$433.76B$64.39B69.3557,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AMGN) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel